CellSource Co., Ltd. (4880.T)
JPY 651.0
(6.03%)
JPY 651.0
(6.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.68 Billion JPY | -49.94% |
| 2022 | -3.12 Billion JPY | -29.7% |
| 2021 | -2.4 Billion JPY | -37.4% |
| 2020 | -1.75 Billion JPY | -32.16% |
| 2019 | -1.32 Billion JPY | -424.33% |
| 2018 | -252.93 Million JPY | -95.03% |
| 2017 | -129.69 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -4.38 Billion JPY | 3.13% |
| 2024 Q2 | -4.53 Billion JPY | 1.62% |
| 2024 Q1 | -4.6 Billion JPY | 1.64% |
| 2023 Q4 | -4.68 Billion JPY | -48.89% |
| 2023 FY | -4.68 Billion JPY | -49.94% |
| 2023 Q3 | -3.14 Billion JPY | 6.42% |
| 2023 Q2 | -3.36 Billion JPY | -10.13% |
| 2023 Q1 | -3.05 Billion JPY | 2.29% |
| 2022 Q2 | -2.37 Billion JPY | -9.03% |
| 2022 Q1 | -2.17 Billion JPY | 9.48% |
| 2022 Q4 | -3.12 Billion JPY | -21.84% |
| 2022 FY | -3.12 Billion JPY | -29.7% |
| 2022 Q3 | -2.56 Billion JPY | -7.86% |
| 2021 Q1 | -1.77 Billion JPY | -1.39% |
| 2021 Q2 | -1.9 Billion JPY | -7.07% |
| 2021 Q3 | -2.07 Billion JPY | -9.12% |
| 2021 Q4 | -2.4 Billion JPY | -15.99% |
| 2021 FY | -2.4 Billion JPY | -37.4% |
| 2020 FY | -1.75 Billion JPY | -32.16% |
| 2020 Q1 | -1.49 Billion JPY | -13.04% |
| 2020 Q4 | -1.75 Billion JPY | -14.84% |
| 2020 Q3 | -1.52 Billion JPY | 2.18% |
| 2020 Q2 | -1.56 Billion JPY | -4.08% |
| 2019 Q3 | -217.43 Million JPY | 0.0% |
| 2019 Q4 | -1.32 Billion JPY | -509.94% |
| 2019 FY | -1.32 Billion JPY | -424.33% |
| 2018 FY | -252.93 Million JPY | -95.03% |
| 2017 FY | -129.69 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 730.552% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -313.026% |
| GNI Group Ltd. | -17.93 Billion JPY | 73.884% |
| Linical Co., Ltd. | -4.46 Billion JPY | -4.933% |
| Trans Genic Inc. | -221.16 Million JPY | -2017.602% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | -6.587% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 2.224% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 426.708% |
| AnGes, Inc. | -3.79 Billion JPY | -23.323% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -1012.976% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 118.803% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -840.167% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -904.291% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -73.069% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -148.039% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -376.864% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | -37.87% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -352.705% |
| Kidswell Bio Corporation | 343.58 Million JPY | 1463.105% |
| PeptiDream Inc. | 3.29 Billion JPY | 242.269% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -381.546% |
| Ribomic Inc. | -2.09 Billion JPY | -123.05% |
| SanBio Company Limited | -3.78 Billion JPY | -23.584% |
| Healios K.K. | -2.19 Billion JPY | -113.858% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -395.68% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -78.476% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -230.506% |
| StemRIM | -8.41 Billion JPY | 44.311% |
| FunPep Company Limited | -1.79 Billion JPY | -161.154% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -119.214% |
| Stella Pharma Corporation | -1.11 Billion JPY | -318.391% |
| TMS Co., Ltd. | -3.44 Billion JPY | -35.886% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 15.699% |
| Cuorips Inc. | -5.56 Billion JPY | 15.78% |
| K Pharma,Inc. | -3.26 Billion JPY | -43.383% |
| Takara Bio Inc. | -32.2 Billion JPY | 85.456% |
| ReproCELL Incorporated | -2.93 Billion JPY | -59.353% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -608.588% |
| StemCell Institute Inc. | -2.83 Billion JPY | -65.1% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -126.655% |
| CellSeed Inc. | -2.01 Billion JPY | -132.772% |